Filing Details

Accession Number:
0001209191-22-009563
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-14 19:56:00
Reporting Period:
2022-02-10
Accepted Time:
2022-02-14 19:56:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1435049 Chinook Therapeutics Inc. KDNY Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1823197 Alan Glicklich C/O Chinook Therapeutics, Inc.
400 Fairview Ave. No., 9Th Floor
Seattle WA 98102
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-02-10 5,668 $0.00 10,282 No 4 M Direct
Common Stock Disposition 2022-02-11 2,391 $12.74 7,891 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units (RSU) Disposition 2022-02-10 5,668 $0.00 5,668 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
11,337 2024-02-10 No 4 M Direct
Footnotes
  1. Restricted stock units convert into common stock on a one-for-one basis.
  2. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  4. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
  5. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.